Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adjuvant Chemotherapy
11%
Advanced Solid Tumors
19%
BRCA mutation
13%
BRCA mutation Carriers
16%
BRCA1, BRCA2
15%
BRCA2
8%
BRCA2 mutation
12%
Breast Cancer Susceptibility Gene 1 (BRCA1)
19%
Cancer Cells
12%
Cancer Patients
11%
Celiac Plexus
8%
Chemotherapy
17%
Clinical Characteristics
11%
Clinical Trials
10%
Clinically Significant
10%
Combination Therapy
13%
Confidence Interval
14%
Early Cancer Detection
8%
First-in-human
9%
Gemcitabine
9%
Germ Cells
25%
Germline BRCA
17%
Germline BRCA mutation
11%
Germline mutation
9%
Hazard Ratio
9%
Homologous Recombination Deficiency
14%
Median Overall Survival
12%
Melanoma
8%
Melanoma Cells
8%
Metastatic Colorectal Cancer (mCRC)
10%
Metastatic Pancreatic Cancer
15%
Monotherapy
20%
Objective Response Rate
10%
Olaparib
17%
Overall Survival
26%
Pancreatic Adenocarcinoma
21%
Pancreatic Cancer
97%
Pancreatic Ductal Adenocarcinoma
73%
PARP Inhibitor (PARPi)
14%
Patient-derived Xenograft
9%
Pembrolizumab
22%
Phase II Trial
15%
Placebo
10%
Previously Treated
16%
Programmed Death-ligand 1 (PD-L1)
9%
Radiosurgery
11%
Survival Characteristics
8%
Tumor
35%
Veliparib
8%
Xenograft
8%
Medicine and Dentistry
Abdominal Cancer
6%
Adenocarcinoma
9%
Adjuvant Chemotherapy
10%
Adverse Event
9%
Arm
16%
Biological Marker
11%
BRCA Mutation
20%
BRCA1
23%
BRCA2
12%
Cancer
8%
Cancer Associated Fibroblast
6%
Cancer Cell
15%
Celiac Plexus
8%
Clinical Trial
16%
Colorectal Carcinoma
7%
Disease Exacerbation
8%
Diseases
26%
DNA Repair
15%
Ex Vivo
6%
Gastroesophageal Junction
9%
Gemcitabine
7%
Gene Mutation
7%
Germ Cell
39%
Hazard Ratio
9%
Immunotherapy
7%
Magnetic Resonance Imaging
6%
Malignant Neoplasm
28%
Melanoma
7%
Melanoma Cell
6%
Metastatic Carcinoma
13%
Monotherapy
6%
Neoplasm
36%
Olaparib
15%
Oncology
9%
Overall Survival
32%
Pancreas Adenocarcinoma
63%
Pancreas Cancer
100%
Pancreatic Ductal Adenocarcinoma
8%
PARP Inhibitor
6%
Pembrolizumab
11%
Personalized Medicine
10%
Phase II Trials
9%
Placebo
10%
Primary Tumor
6%
Progression Free Survival
8%
Radiosurgery
8%
Retrospective Study
6%
Stomach Adenocarcinoma
8%
Veliparib
8%
Xenograft
13%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
9%
Abemaciclib
5%
Adenocarcinoma
12%
Adverse Event
18%
Antitumor Activity
8%
Biological Marker
8%
Chemotherapy
30%
Cisplatin
6%
Clinical Trial
12%
Colon Carcinoma
10%
Colorectal Carcinoma
15%
Combination Therapy
14%
Disease Exacerbation
8%
Diseases
29%
Fibrinogen
5%
Gemcitabine
14%
Malignant Neoplasm
26%
Mammalian Target of Rapamycin Inhibitor
5%
Metastatic Colorectal Cancer
11%
Mitomycin
5%
Monotherapy
21%
Neoplasm
41%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
5%
Nivolumab
5%
Olaparib
14%
Overall Survival
33%
Oxaliplatin
7%
Paclitaxel
7%
Pancreas Adenocarcinoma
47%
Pancreas Cancer
68%
Pembrolizumab
28%
Pharmacokinetics
5%
Phase II Trials
10%
Placebo
10%
Prodrug
5%
Progression Free Survival
9%
Receptor Antibody
5%
Retrospective Study
5%
Small Interfering RNA
8%
Solid Malignant Neoplasm
24%
Somatomedin
5%
Veliparib
8%